Skip to main content

Tenax Therapeutics, Inc. (TENX)

NASDAQ: TENX · IEX Real-Time Price · USD
1.26
-0.03 (-2.33%)
At close: Nov 26, 2021 1:00 PM
1.34
0.08 (6.35%)
After-hours:Nov 26, 2021 1:44 PM EST
Market Cap31.75M
Revenue (ttm)n/a
Net Income (ttm)-32.09M
Shares Out25.20M
EPS (ttm)-2.22
PE Ration/a
Forward PE3.63
Dividendn/a
Ex-Dividend Daten/a
Volume131,612
Open1.32
Previous Close1.29
Day's Range1.26 - 1.27
52-Week Range0.95 - 3.68
Beta2.07
AnalystsBuy
Price Target4.75 (+277.0%)
Earnings DateNov 15, 2021

About TENX

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeu...

IndustryBiotechnology
Founded1967
CEOJohn Kelley
Employees9
Stock ExchangeNASDAQ
Ticker SymbolTENX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 276.98% from the latest price.

Price Target
$4.75
(276.98% upside)
Analyst Consensus: Buy

News

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

1 week ago - Business Wire

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.

1 month ago - Business Wire

Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announced company to present at H.C. Wainwright Conference September 13-15, 2021

2 months ago - Business Wire

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces second quarter 2021 financial results and provides business update.

3 months ago - Business Wire

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patient...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study

3 months ago - Business Wire

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.

3 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary du...

4 months ago - Newsfile Corp

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces retirement of CEO Anthony A. DiTonno, Christopher T. Giordano as new CEO and $10 million PIPE.

4 months ago - Business Wire

Tenax Therapeutics Set to Join Russell Microcap® Index

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021

5 months ago - Business Wire

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

6 months ago - Business Wire

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced the publication of positive data from the company's Phase 2 HELP Study in the Journal of American College of Cardiology: Heart Failure

7 months ago - Business Wire

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to N...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.

7 months ago - Business Wire

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update

7 months ago - Business Wire

Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) to present company overview at H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021

8 months ago - Business Wire

Tenax Therapeutics, Inc. Expands Board of Directors

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board.

8 months ago - Business Wire

Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med

10 months ago - Business Wire

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other symbols:ACRSCYADGRTSMRUSNERV
10 months ago - Benzinga

TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precision Med as Shares Rocket

Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precisi...

10 months ago - InvestorPlace

Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.

10 months ago - Business Wire

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update

1 year ago - Business Wire

Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th

1 year ago - Business Wire

Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST

1 year ago - Business Wire

Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Cor...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.

1 year ago - Business Wire

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT

1 year ago - Business Wire

Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

1 year ago - Business Wire